Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection

Journal of Clinical Virology

Volumn 43, Issue 3, 2008, Pages 284-286

  Sungkanuparph, Somnuek ^a   Sukasem, Chonlaphat ^a   Manosuthi, Weerawat ^a,b   Wiboonchutikul, Surasak ^a   Piyavong, Bucha ^a   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

CRF01_AE; HIV; Mutations; Resistance; Subtype A E; Tipranavir

Indexed keywords

PROTEINASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PREVALENCE; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PYRIDINES; PYRONES; VIRAL LOAD;

EID: 53649091416     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.07.002     Document Type: Article

References (18)

1. Ariyoshi K., Matsuda M., Miura H., Tateishi S., Yamada K., and Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 33 (2003) 336-342
2. Baxter J., Schapiro J., Boucher C., et al. Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80 (2006) 10794-10801
3. Caride E., Hertogs K., Larder B., et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 23 (2001) 193-202
4. Egger M., Hirschel B., Francioli P., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315 (1997) 1194-1199
5. Gallant J.E. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 44 (2007) 453-455
6. Grant R.M., Kuritzkes D.R., Johnson V.A., et al. Accuracy of the Trugene HIV-1 genotyping kit. J Clin Microbiol 41 (2003) 1586-1593
7. Johnson V.A., Brun-Vézinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15 (2007) 119-125
8. Kantor R., Katzenstein D.A., Efron B., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2 (2005) e112
9. Kuritzkes D.R., Grant R.M., Feorino P., et al. Performance characteristics of the Trugene HIV-1 genotyping kit and the Opengene DNA sequencing system. J Clin Microbiol 41 (2003) 1594-1599
10. Kuritzkes D.R. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 18 (2004) 259-273
11. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353 (1999) 863-868
12. Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., and Sungkanuparph S. Survival rate and risk factors of mortality among HIV/Tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43 (2006) 42-46
13. Markowitz M., Slater L.N., Schwartz R., et al. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defic Syndr 45 (2007) 401-410
14. Palmer S., Alaeus A., Albert J., and Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 14 (1998) 157-162
15. Poveda E., de Mendoza C., Parkin N., et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 22 (2008) 611-616
16. Walmsley S.L., Cotte L., Rusconi S., et al. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS 21 (2007) 2245-2248
17. Weidle P.J., Malamba S., Mwebaze R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360 (2002) 34-40
18. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 60 (2007) 1195-1205